CDK4 and metastatic neoplasm: Noteworthily, ESMO recommendations reported that postponing the incorporation of a CDK4/6 inhibitor in the first line for patients presenting with special patterns of disease (eg, bone only, low burden, de novo metastatic disease) could be an option, especially in the older population [10].